Syntis Bio Closes $38 Million Financing to Accelerate Oral Therapies for Obesity and Rare Diseases
Capital from the Series A financing and grant funding will advance development of SYNT, an orally delivered, transient polymer coating for the small intestine that controls nutrient uptake, enhances gut-restricted enzyme efficacy and increases systemic drug absorption for up to 24 hours. The funding also enables the advancement of lead program SYNT-101 through Phase 1 studies as a once-daily treatment for obesity, as well as initiation of Phase 1 studies for SYNT-202, a first-in-class oral enzyme therapy for homocystinuria, a rare pediatric amino acid disorder. To date, SYNT-101 has demonstrated strong pre-clinical safety and weight loss data, as well as clinical advancements in safety, mechanism of action and pathways for controlling weight.
'We're grateful for the continued support and enthusiasm of our new and existing investors, who share our vision to revolutionize both chronic and rare disease treatment through safe, effective oral therapies,' said Rahul Dhanda, CEO and co-founder of Syntis Bio. "This oversubscribed Series A round coupled with these non-dilutive grants validates and accelerates the promise of SYNT-101 in obesity and, more broadly, our SYNT platform technology to unlock the small intestine's full therapeutic potential to meaningfully improve human health.'
Syntis also announced the addition of two members to the company's Board of Directors, Chenny Zhang, director at Cerberus Ventures, and Michael Nannizzi, director of investments at W. R. Berkley. Mr. Dhanda added, 'I'm thrilled to welcome Chenny and Michael to our board. Michael has actively advised Syntis since our early days, reflecting W. R. Berkley's consistent strategic support, and adding Chenny augments the strong foundation we have built. Her extensive life sciences experience at Cerberus Ventures and previously at In-Q-Tel will be invaluable as Syntis Bio enters our next growth phase focused on strategic partnerships and platform innovation.'
'While high-cost, complex development processes continue to limit many Americans' access to essential medicines, Syntis' SYNT platform represents a fundamentally novel approach to the oral delivery of biologics. We believe SYNT, with its breakthrough technology and platform potential, is poised to significantly expand patient access and redefine what is possible in drug delivery,' said Ms. Zhang. 'I look forward to working closely with the team to realize the full potential of their disruptive platform and pipeline.'
About SYNT-101
SYNT-101 is being developed as a once-daily pill for the treatment of obesity. SYNT-101 works by transiently blocking nutrient absorption in the duodenum, the upper part of the small intestine, and redirecting nutrients to the distal small intestine to stimulate the natural secretion of satiety and metabolism-regulating hormones, including GLP-1. This mechanism, known as duodenal nutrient exclusion, is a key contributor to the efficacy of gastric bypass surgery, which remains the gold standard for weight loss and metabolic disease management. Recent preclinical data demonstrated 100% preservation of lean muscle mass with consistent 1% weekly weight loss in rodent models, while first-in-human data showed that SYNT-101 demonstrated strong evidence of nutrient redirection and satiety hormone modulation. Importantly, SYNT-101 displayed strong safety and tolerability across both studies, with no adverse events reported.
About SYNT™ Technology
SYNT-101 leverages the power of SYNT™ (SYN thetic T issue-lining) oral therapeutic technology that optimizes therapeutic effects in the small intestine, the body's nexus for metabolic control, digestion and drug absorption. SYNT uses mussel-inspired polymer chemistry to deliver a safe, transient polydopamine coating to catalase-rich tissues, like the duodenum. After successful deployment in the gastrointestinal tract, the polydopamine lining is sustained for up to 24 hours, after which it is naturally and safely cleared from the body. SYNT is highly versatile and can achieve a variety of therapeutic effects. In addition to nutrient exclusion, SYNT can be engineered to install and sustain gut-restricted enzymes in the small bowel, enhance the oral bioavailability of drugs, and target new tissues throughout the body. Data from more than 100 preclinical pig studies conducted by MIT and Syntis demonstrate that SYNT can achieve 70% glucose blocking, 20 times improved enzyme activity, and 4-10 times increased oral drug bioavailability.
About Syntis Bio
Syntis Bio is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestine's unique biology to provide more accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the world's most prevalent conditions. Syntis is rapidly advancing a pipeline of oral therapies engineered for targeted activity in the small intestine, the body's nexus for metabolic control, digestion and drug absorption. Alongside its lead obesity program, SYNT-101, the company is advancing a portfolio of therapies targeting orphan metabolic diseases and intestinal-related disorders. Syntis is headquartered in Boston, MA. For more information, please visit www.syntis.bio and follow us on LinkedIn.
NIH Grant Acknowledgment
Research reported in this press release was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Numbers R44DK138869 and R44DK141341. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
22 minutes ago
- Business Wire
OPM Announces Its 2025 Half-Year Financial Results and Provides an Update on Its Clinical Developments and Financial Position
DIJON, France--(BUSINESS WIRE)--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces its financial results for the first half of 2025, as approved by the Board of Directors on July 31, 2025. Philippe GENNE, Chairman and CEO of Oncodesign Precision Medicine, comments: "To date, it remains impossible to raise funds on Euronext for a biotechnology company that needs to conduct clinical proof-of-concept trials. As a result, our hopes for revenue and therefore cash availability rest primarily on discussions with potential buyers of our assets. The various cost-cutting measures we have taken since the beginning of this year are enabling us to continue these discussions over time, and the last quarter will be crucial in this regard." Karine LIGNEL, Managing Director and COO of Oncodesign Precision Medicine adds: "In a very difficult financial environment, we have taken management decisions that have enabled us to significantly reduce our expenses and thus extend our cash flow horizon as much as possible. We have also set up an equity financing line to deal with market uncertainties. Nevertheless, the situation remains complicated, and we are making every effort to secure a partnership for one of our assets." Key financial data A cost reduction program was implemented in the first half of 2025: Negotiations were held with the banks and BPI that granted the loan, resulting in a six-month deferral of principal repayments starting in April 2025 Expenses were reduced through The layoff of five employees in early 2025 A 50% reduction in the compensation of non-salaried corporate officers A freeze on salaries and bonus payments for the 2024 fiscal year A reduction in spending on non-priority programs. In terms of cash flow, rather than from an accounting perspective, this results in a reduction in payroll costs of €242k in the first half of 2025 and a projected reduction of €440k in the second half of this year. The reduction in expenditure is particularly significant for the item 'subcontracting and fees,' which will fall from €2,900k in the first half of 2024 to €1,773k in the first half of 2025. R&D expenses amounted to €1.74 million in the first half of 2025, compared with €3.61 million in the same period last year, as the company focused its efforts on the clinical development of OPM-101. Reintegration, in close collaboration with Servier, of all OPM-201 data and product stocks The most significant financial item in the first half of 2025 is the reintegration, as provided for in the partnership agreement, of the stock of OPM-201 GMP material produced by Servier. As this reintegration is being carried out without financial competing, OPM has called upon an external expert to determine fair value for these stocks. This expert carried out three different valuations to arrive at this fair value. A summary of these valuations is shown in the table below: The expert concluded that the fair value of these inventories falls within a range of €13 million to €16.2 million. OPM used the lower end of this range. OPM's revenue for the first half of 2025 was €0.1 million, the same as in the first half of 2024. Other income mainly consists of subsidies amounting to €0.3 million and €0.3 million in provision reversals. OPM's financial result was (€0.26) million, compared with (€0.1) million in the same period last year, mainly due to interest on outstanding loans and financial income from cash investments. OPM recorded €0.4 million in R&D tax credits in the first half of 2025, down 52% compared to last year. The amount of R&D tax credits was reduced by the amount of public aid, the R&D expenditure base decreased, and the rules for collecting R&D tax credits changed (exclusion of technology watch patents, etc.). OPM's half-year net income thus stands at €9,846k, due to the integration of OPM-201 inventories at an estimated value of €13m. Cash position of €2.5m at June 30, 2025 As of June 30, 2025, OPM had cash reserves of €2.5 million, before receiving the Research Tax Credit, compared to €9.6 million (including the Research Tax Credit) as of June 30, 2024. The Research Tax Credit, amounting to €1.1 million, was received in July 2025. OPM has access to a maximum €5 million equity financing facility, which it has not yet used. The Company is in discussions with financial and pharmaceutical partners with the goal of signing a partnership agreement or raising funds. 2025 perspectives OPM has submitted its Phase 1b/2a protocol for the REVERT study evaluating OPM-101 in patients with advanced melanoma resistant to anti-PD1 and is awaiting a response from Swiss ethics institutions. The first patient is expected to be enrolled by the end of 2025. Work on radioligands is continuing as part of the COMETE project. Partnership prospects or transfer mainly focus on the two most advanced molecules to date (OPM-101 and OPM-201). OPM's goal is to license or transfer OPM-101 at the end of Phase 2a to a pharmaceutical partner who will complete its development and commercialization. While we do not anticipate licensing or sales before the end of this phase in 2027, we are considering the possibility of a pharmaceutical partner taking a licensing option with the payment of an exclusivity fee, giving them first refusal on the results. For OPM-201, the objective is to find a partnership similar to the one we found with Servier in 2019 or a buyer. Availability of the 2025 half-year financial report The 2025 half-year financial report will be available on the company's website, within the legal deadline, before October 31, 2025. About Oncodesign Precision Medicine (OPM) Oncodesign Precision Medicine (OPM), founded in 2022, is a biopharmaceutical company specializing in precision medicine, dedicated to discovering treatments for resistant and metastatic cancers. OPM currently has two kinase inhibitors in clinical phase: OPM-101, intended for the treatment of chronic immuno-inflammatory digestive diseases and immuno-oncology, has demonstrated a significant therapeutic margin and absence of toxicity in its phase I healthy volunteers, with the start of phase 1b/2a in Oncology scheduled for early 2025. OPM-201, initially licensed to Servier and intended for the treatment of Parkinson's disease, completed its phase I trial in healthy volunteers at the end of 2024, and was reintegrated into OPM's portfolio. Both molecules come from the Nanocyclix ® technology platform, which enables the design and selection of small, highly effective and selective macrocyclic kinase inhibitors. We now have 12,000 molecules in our library and will be using AI to accelerate the discovery of drug candidates while reducing the cost of this phase. OPM's other two technology platforms are: OncoSNIPER, for the selection of therapeutic targets using artificial intelligence, on which we have a partnership with Servier for the search for targets in pancreatic cancer, PROMETHE ® for the design and selection of radiolabeled biological molecules for systemic radiotherapy, on which we are currently discussing partnerships with vectorization manufacturers. OPM, co-founded by Philippe Genne, Jan Hoflack and Karine Lignel, is based in Dijon, at the heart of the university and hospital cluster, and employs 14 people. More info at: Forward-looking statements This document contains forward-looking statements and estimates with respect to the financial condition, results of operations, strategy, plans and future performance of the Company and the market in which it operates. Some of these statements, forecasts and estimates can be identified by the use of words such as, without limitation, "believes", "anticipates", "expects", "projects", "plans", "seeks", "estimates", "may", "will" and "continue" and other similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were believed to be reasonable when they were made but which may not prove to be correct. Actual events are difficult to predict and may depend on factors beyond the Company's control. Consequently, the actual results, financial conditions, performance or achievements of the Company, or industry results, may differ materially from future results, performance or achievements as expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representation is made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, the forward-looking statements, forecasts and estimates speak only as of the date of publication of this document. The Company disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any change in the Company's expectations with regard thereto, or any change in events, conditions or circumstances on which these statements, forecasts or estimates are based, except as required by French law.
Hamilton Spectator
an hour ago
- Hamilton Spectator
WestKam Gold Corp. Mobilizes Crews for Prospecting and Soil Sampling on Will Property, Mt. Williams, B.C.
Vancouver, B.C., July 31, 2025 (GLOBE NEWSWIRE) — WestKam Gold Corp. (the 'Company' or 'WestKam') is pleased to announce that field crews are being mobilized to commence a prospecting and soil sampling program on the Company's 100%-owned Will Project, located on Mt. Williams near Goldbridge, British Columbia. The Will Project encompasses 1,142.47 hectares of highly prospective terrain and is in good standing through January 30, 2027. The 2025 exploration campaign will focus on a zone of listwanite alteration in the upper reaches of Mt. Williams, an area with geological characteristics conducive to gold and antimony mineralization. The targeted alteration zone is situated on trend with the Minto-Olympic shear zone, currently being advanced by Endurance Gold Corp., and is interpreted to share a similar structural and lithological setting. Listwanite-hosted orogenic systems are globally recognized for their association with significant gold deposits. Antimony is commonly associated in such settings—particularly in structurally controlled quartz-carbonate veining in proximity to ultramafic rocks. The program will include systematic soil sampling, geological mapping and prospecting, aimed at delineating geochemical anomalies and identifying potential drill targets within the target area shown on Figure #1. Peter Laipnieks, President commented: 'We are excited to initiate more work on the Will Project, which represents a compelling opportunity for discovery. The combination of listwanite alteration, favorable structural setting, and the potential for both gold and antimony mineralization positions this property as a high-priority exploration target for WestKam.' WestKam remains committed to responsible exploration practices and ongoing collaboration with local communities and stakeholders as operations advance on Mt. Williams. Figure # 1 – Will Property Area with Proposed Soil Grid Area Please click to view image Qualified Person Lorne Warner, P. Geo, is a qualifies qualified person as defined by National Instrument 43-101 and has reviewed and approved the scientific and technical disclosure in this news release. About WestKam WestKam Gold Corp. is focused on acquiring and developing mineral properties, with strong potential to host significant resources, in Western Canada . We are looking for additional projects that are in an established mining district with highly prospective geology that could host significant resources. ON BEHALF OF THE BOARD OF DIRECTORS 'Peter Laipnieks' Peter Laipnieks, President & CEO Contacts: WestKam Gold Corp. Suite 900, 570 Granville Street Vancouver, BC V6C 3P1 Contact: Investor Relations: 250.216.5671 Email: westkam007@ Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-looking information All statements included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. In particular, this news release contains forward-looking information regarding the timing of completing and filing of the Interim Filings. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will prove inaccurate, certain of which are beyond the Company's control. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not intend to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.
Business Upturn
10 hours ago
- Business Upturn
Increases Total Mineral Inventory: Provides Results of Updated Mineral Resource and Reserves
By GlobeNewswire Published on July 31, 2025, 10:30 IST Increases Total Mineral Inventory: Provides Results of Updated Mineral Resource and Reserves Serabi Gold plc ('Serabi' or the 'Company') (AIM:SRB, TSX:SBI, OTCQX:SRBIF), the Brazilian focused gold mining and development company, is pleased to announce updated Mineral Reserve estimates and Mineral Resource estimates for its Palito Mine, prepared in accordance with the standard of CIM and Canadian National Instrument 43-101, with an effective date of 1 April, 2025 as outlined below (all financial amounts are expressed in U.S. dollars unless otherwise indicated) . HIGHLIGHTS Proven and Probable ('2P') Reserves totalling 162,600 ounces (706,000 tonnes at 7.2 g/t Au) compared to 206,400 ounces (824,800 tonnes @ 7.8 g/t Au) in July 2023. Reserve life is equivalent to over six years of operations at current production levels, without considering conversion of additional mineral resources. Measured and Indicated ('M&I') Resources of 388,400 ounces of contained gold (1,252,900 tonnes @ 9.6 g/t Au), a 3% increase compared to 377,800 (1,166,300 tonnes @ 10.1 g/t) in December 2023. Inferred Resources of 163,900 ounces (690,200 tonnes @ 7.4 g/t Au), a 7% increase compared to 153,900 ounces (682,400 tonnes @ 7.0 g/t Au in July 2023). NCL Ingeniería y Construcción SpA of Santiago de Chile ('NCL') is preparing this Mineral Resource and Mineral Reserve estimation together with a new 43-101 Technical Report which is expected to be issued within 45 days of the date of this release. Mike Hodgson CEO commented: 'This updated Mineral Resource demonstrates Serabi's ability to replenish resources on a consistent basis. We have regularly maintained our ability to replace production with new resources and in this instance, the combined Measured, Indicated and the Inferred resource categories have increased by 4% since 2023. The Company has a strong track record of maintaining a ~500koz ounces total mineral inventory at the Palito Complex and this latest estimate is no different as we increase to 552koz. Within this mineral resource inventory, we have reported a 2P Mineral Reserve of ~163koz, equating to over six years of reserve life at current extraction rates, excluding any future resource to reserve conversion. For a narrow vein mine, this is a great position to be in. With São Chico on care and maintenance since 2022, the 2023 estimated resources and reserves have simply been restated here, albeit these resources and reserves were calculated at a more conservative gold price and exchange rate. In early 2025 we embarked on a $9m brownfield surface exploration drill programme spread across the Palito Complex and Coringa, approximately 50% of this budget will be used at Palito to test extensions of known orebodies. As this drill programme did not commence until March, this updated resource estimate does not include results from the exploration programme. We therefore look forward to an update in early 2026, when we do expect to incorporate results from our 'aggressive' brownfield programme. In the meantime, this increase, which excludes the surface drill programme, is especially pleasing.' The Mineral Reserve estimate was prepared by Mr Carlos Guzman of NCL Ingeniería y Construcción SpA, who is a Qualified Person under the Canadian National Instrument 43-101. The Mineral Resource estimate was prepared by Mr Nicolas Fuster of NCL Ingeniería y Construcción SpA, who is a Qualified Person under the Canadian National Instrument 43-101. Mineral Reserve Estimates The updated Mineral Reserve estimates for the Palito Mine and the São Chico Mine are based on data as at 1st April 2025. Table 1: Palito Complex Mineral Reserve Statement as of April 1, 2025 Mineral Reserve Statement for the Palito Complex (Palito and São Chico Mines) Palito São Chico Combined Tonnes Grade Contained Tonnes Grade Contained Tonnes Grade Contained (000's) (g/t Au) (000's oz) (000's) (g/t Au) (000's oz) (000's) (g/t Au) (000's oz) Proven 422.4 7.7 103.8 46.1 8.2 12.2 468.5 7.7 116.0 Probable 223.6 6.0 43.1 14.1 7.7 3.5 237.7 6.1 46.6 Total Reserves 645.9 7.1 147.0 60.2 8.1 15.6 706.1 7.2 162.6 Notes to Palito Complex Mineral Reserve Estimates Mineral Reserves have been rounded to reflect the relative accuracy of the estimates. Proven Mineral Reserves are reported within the Measured classification domain, and Probable Mineral Reserves are reported within the Indicated classification domain. Palito Mine Proven and Probable Mineral Reserves are inclusive of external mining dilution and mining loss and are reported at a cut-off grade of 3.98 g/t gold for Palito Mine and assuming an underground shrinkage mining scenario, a gold price of US$2,000/oz, a 5.5:1 Brazilian Real to U.S. Dollar exchange rate, and metallurgical recoveries of 93.2%. São Chico Mine Proven and Probable Mineral Reserves are inclusive of external mining dilution and mining loss and are reported at a cut-off grade of 4.0 g/t gold and assuming an underground shrinkage mining scenario, a gold price of US$1,800/oz, a 5.0:1 Brazilian Real to U.S. Dollar exchange rate, and metallurgical recoveries of 93.8%, as estimated in 2023 and re-stated in this release . Serabi is the operator and owns 100% of the Palito Mine such that gross and net attributable mineral reserves are the same. The mineral reserve estimate was prepared by NCL in accordance with the standard of CIM and NI 43-101, with an effective date of April 1, 2025, and audited and approved by Mr. Carlos Guzmán of NCL, who is a Qualified Person under NI 43-101. Mineral Resource Estimates The updated Mineral Resource estimates for the Palito Mine and the Sao Chico Mine are based on data as at 1st April 2025 and 31st July 2023, respectively. Table 2: Mineral Resource Statement, Palito Mine as of April 1, 2025 Classification Tonnes Grade Contained (000's) (g/t Au) (000's) Measured 769 10.8 267.5 Indicated 333 7.7 82.5 Measured and Indicated 1,102 9.9 350.0 Inferred 682 7.4 161.8 Notes to Palito Mine Mineral Resource Statement Mineral Resources are not Mineral Reserves and have not demonstrated economic viability. Mineral Resources are reported inclusive of Mineral Reserves. Figures are rounded to reflect the relative accuracy of the estimates. Mineral Resources are reported within classification domains with no dilution applied at a cut-off grade of 2.92 g/t gold assuming an underground extraction scenario, a gold price of US$2,500/oz, metallurgical recovery of 95% and exchange rate of R$ 6.0/US$. Polygonal techniques were used for Resources estimates. The mineral resource estimate was prepared by NCL in accordance with the standard of CIM and NI 43-101, with an effective date of April 1, 2025, and audited and approved by Mr. Nicolas Fuster of NCL, who is a Qualified Person under NI 43-101. Table 3: Mineral Resource Statement, São Chico Mine as of July 31, 2023 Classification Tonnes Grade Contained (000's) (g/t Au) (000's) Measured 123 8.1 31.9 Indicated 29 7.1 6.5 Measured and Indicated 151 7.9 38.4 Inferred 8 6.5 1.7 Notes to Mineral Resource Statement, São Chico Mine Mineral Resources are not Mineral Reserves and have not demonstrated economic viability. Mineral Resources are reported inclusive of Mineral Reserves. Figures are rounded to reflect the relative accuracy of the estimates. Mineral Resources are reported within classification domains with no dilution applied at a COG of 3.32 g/t gold assuming an underground extraction scenario, a gold price of US$1,950/oz, metallurgical recovery of 95% and exchange rate of R$ 5.5/US$3D block model used for Resource estimates. Polygonal techniques were used for Resources estimates. Qualified Persons and Quality Control The scientific and technical information contained in this news release pertaining to the Palito Complex has been reviewed and approved by the following Qualified Persons under National Instrument 43-101 – Standards of Disclosure for Mineral Projects ('NI 43-101'): Carlos Guzman,RM CMC, FAusIMM, NCL Ingeniería y Construcción SpA Gustavo Tapia, RM CMC, Metallurgical and Process Consultant, GT Metallurgy Nicolas Fuster, RM CMC, MAusIMM, NCL Ingeniería y Construcción SpA The Qualified Persons have verified the information disclosed herein, including the sampling, preparation, security and analytical procedures underlying the information or opinions contained in this announcement in accordance with standards appropriate to their qualifications. Technical Report A Technical Report prepared by NCL Ingeniería y Construcción SpA. In accordance with NI 43-101 will be filed on SEDAR ( ) within 45 days of this release as well as on the Company's website About Serabi Gold plc Serabi Gold plc is a gold exploration, development and production company focused on the prolific Tapajós region in Para State, northern Brazil. The Company has consistently produced 30,000 to 40,000 ounces per year with the Palito Complex and is planning to double production in the coming years with the construction of the Coringa Gold project. Serabi Gold plc recently made a copper-gold porphyry discovery on its extensive exploration licence. The Company is headquartered in the United Kingdom with a secondary office in Toronto, Ontario, Canada. The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018. The person who arranged for the release of this announcement on behalf of the Company was Andrew Khov, Vice President, Investor Relations & Business Development. Enquiries SERABI GOLD plc Michael Hodgson t +44 (0)20 7246 6830 Chief Executive m +44 (0)7799 473621 Colm Howlin Chief Financial Officer m +353 89 6078171 Andrew Khov m +1 647 885 4874Vice President, Investor Relations & Business Development e [email protected] BEAUMONT CORNISH Limited Nominated Adviser & Financial Adviser Roland Cornish / Michael Cornish t +44 (0)20 7628 3396 PEEL HUNT LLP Joint UK Broker Ross Allister / Georgia Langoulant t +44 (0)20 7418 9000 TAMESIS PARTNERS LLP Joint UK Broker Charlie Bendon/ Richard Greenfield t +44 (0)20 3882 2868 CAMARCO Financial PR – Europe Gordon Poole / Emily Hall t +44 (0)20 3757 4980 Assay Results Assay results reported within this release include those provided by the Company's own on-site laboratory facilities at Palito and have not yet been independently verified. Serabi closely monitors the performance of its own facility against results from independent laboratory analysis for quality control purpose. As a matter of normal practice, the Company sends duplicate samples derived from a variety of the Company's activities to accredited laboratory facilities for independent verification. Since mid-2019, over 10,000 exploration drill core samples have been assayed at both the Palito laboratory and certified external laboratory, in most cases the ALS laboratory in Belo Horizonte, Brazil. When comparing significant assays with grades exceeding 1 g/t gold, comparison between Palito versus external results record an average over-estimation by the Palito laboratory of 6.7% over this period. Based on the results of this work, the Company's management are satisfied that the Company's own facility shows sufficiently good correlation with independent laboratory facilities for exploration drill samples. The Company would expect that in the preparation of any future independent Reserve/Resource statement undertaken in compliance with a recognized standard, the independent authors of such a statement would not use Palito assay results without sufficient duplicates from an appropriately certificated laboratory. Forward-looking statements Certain statements in this announcement are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', 'should' ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors. Several factors could cause actual results to differ materially from the results discussed in the forward-looking statements including risks associated with vulnerability to general economic and business conditions, competition, environmental and other regulatory changes, actions by governmental authorities, the availability of capital markets, reliance on key personnel, uninsured and underinsured losses and other factors, many of which are beyond the control of the Company. Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward looking statements. Qualified Persons Statement The scientific and technical information contained within this announcement has been reviewed and approved by Michael Hodgson, a Director of the Company. Mr Hodgson is an Economic Geologist by training with over 30 years' experience in the mining industry. He holds a BSc (Hons) Geology, University of London, a MSc Mining Geology, University of Leicester and is a Fellow of the Institute of Materials, Minerals and Mining and a Chartered Engineer of the Engineering Council of UK, recognizing him as both a Qualified Person for the purposes of Canadian National Instrument 43-101 and by the AIM Guidance Note on Mining and Oil & Gas Companies dated June 2009. Notice Beaumont Cornish Limited, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting as nominated adviser to the Company in relation to the matters referred herein. Beaumont Cornish Limited is acting exclusively for the Company and for no one else in relation to the matters described in this announcement and is not advising any other person and accordingly will not be responsible to anyone other than the Company for providing the protections afforded to clients of Beaumont Cornish Limited, or for providing advice in relation to the contents of this announcement or any matter referred to in it. Neither the Toronto Stock Exchange, nor any other securities regulatory authority, has approved or disapproved of the contents of this news release See for more information and follow us on X @Serabi_Gold APPENDIX Mineral Reserves and Resources The Company estimates and discloses mineral reserves and resources using the definitions adopted by the Canadian Institute of Mining, Metallurgy and Petroleum, and in accordance with NI 43-101. Further details are available at See the 'Glossary of Geological and Mining Terms' for complete definitions of mineral reserves and mineral resources. About Mineral Resources Mineral resources are not mineral reserves and do not have demonstrated economic viability but do have reasonable prospect for economic extraction. They fall into three categories: measured, indicated, and inferred. The reported mineral resources are stated inclusive of mineral reserves. Measured and indicated mineral resources are sufficiently well-defined to allow geological and grade continuity to be reasonably assumed and permit the application of technical and economic parameters in assessing the economic viability of the mineral resource. Inferred mineral resources are estimated on limited information not sufficient to verify geological and grade continuity or to allow technical and economic parameters to be applied. Inferred mineral resources are too speculative geologically to have economic considerations applied to them. There is no certainty that mineral resources of any category will be upgraded to mineral reserves. Important Information about Mineral Reserve and Resource Estimates Whilst the Company takes all reasonable care in the preparation and verification of the mineral reserve and resource figures, the figures are estimates based in part on forward-looking information. Estimates are based on management's knowledge, mining experience, analysis of drilling results, the quality of available data and management's best judgment. They are, however, imprecise by nature, may change over time, and include many variables and assumptions including geological interpretation, commodity prices and currency exchange rates, recovery rates, and operating and capital costs. There is no assurance that the indicated levels of metal will be produced, and the Company may have to re-estimate the mineral reserves based on actual production experience. Changes in the metal price, production costs or recovery rates could make it unprofitable to operate or develop a particular deposit for a period of time. A comparison of the updated Mineral Reserve Estimates as at 1 April 2025 with the previously reported Mineral Reserve Estimates as at 31 July 2023 published on 20 November 2023 is set out below. Comparison of Mineral Reserves for the Palito Mine, Para, Brazil April 2025 July 2023 Tonnes Grade Contained Tonnes Grade Contained (000's) (g/t Au) (000's oz) (000's) (g/t Au) (000's oz) Proven 422 7.7 103.8 568 8.1 147.5 Probable 224 6.0 43.1 197 6.8 43.2 Proven & Probable Reserves 646 7.1 147.0 765 7.8 190.7 A comparison of the updated Mineral Resource Estimates as at 1 April 2025 with the previously reported Mineral Resource Estimates as at 31 July 2023 published on 20 November 2023 is set out below. Comparison of Mineral Resources for the Palito Mine, Para, Brazil April 2025 July 2023 Tonnes Grade Contained Tonnes Grade Contained (000's) (g/t Au) (000's oz) (000's) (g/t Au) (000's oz) Measured Resources 769 10.8 268 772 11.0 274 Indicated Resources 333 7.7 83 243 8.4 66 Measured & Indicated Resources 1,102 9.9 350 1,015 10.4 339 Inferred Resources 682 7.4 162 674 7.0 152 GLOSSARY OF TERMS The following is a glossary of technical terms: 'Ag' means silver. 'Au' means gold. 'assay' in economic geology, means to analyse the proportions of metal in a rock or overburden sample; to test an ore or mineral for composition, purity, weight or other properties of commercial interest. 'CIM' means the Canadian Institute of Mining, Metallurgy and Petroleum. 'chalcopyrite' is a sulphide of copper and iron. 'Cu' means copper. 'cut-off grade' the lowest grade of mineralised material that qualifies as ore in a given deposit; rock of the lowest assay included in an ore estimate. 'dacite porphyry intrusive' a silica-rich igneous rock with larger phenocrysts (crystals) within a fine-grained matrixi 'deposit' is a mineralised body which has been physically delineated by sufficient drilling, trenching, and/or underground work, and found to contain a sufficient average grade of metal or metals to warrant further exploration and/or development expenditures; such a deposit does not qualify as a commercially mineable ore body or as containing ore reserves, until final legal, technical, and economic factors have been resolved. 'electromagnetics' is a geophysical technique tool measuring the magnetic field generated by subjecting the sub-surface to electrical currents. 'garimpo' is a local artisanal mining operation 'garimpeiro' is a local artisanal miner. 'geochemical' refers to geological information using measurements derived from chemical analysis. 'geophysical' refers to geological information using measurements derived from the use of magnetic and electrical readings. 'geophysical techniques' include the exploration of an area by exploiting differences in physical properties of different rock types. Geophysical methods include seismic, magnetic, gravity, induced polarisation and other techniques; geophysical surveys can be undertaken from the ground or from the air. 'gossan' is an iron-bearing weathered product that overlies a sulphide deposit. 'grade' is the concentration of mineral within the host rock typically quoted as grams per tonne (g/t), parts per million (ppm) or parts per billion (ppb). 'g/t' means grams per tonne. 'granodiorite' is an igneous intrusive rock similar to granite. 'hectare' or a 'ha' is a unit of measurement equal to 10,000 square metres. 'igneous' is a rock that has solidified from molten material or magma. 'IP' refers to induced polarisation, a geophysical technique whereby an electric current is induced into the sub-surface and the conductivity of the sub-surface is recorded. 'intrusive' is a body of rock that invades older rocks. 'Indicated Mineral Resource An Indicated Mineral Resource is that part of a Mineral Resource for which quantity, grade or quality, densities, shape and physical characteristics are estimated with sufficient confidence to allow the application of Modifying Factors in sufficient detail to support mine planning and evaluation of the economic viability of the deposit. Geological evidence is derived from adequately detailed and reliable exploration, sampling and testing and is sufficient to assume geological and grade or quality continuity between points of observation. An Indicated Mineral Resource has a lower level of confidence than that applying to a Measured Mineral Resource and may only be converted to a Probable Mineral Reserve. 'Inferred Mineral Resource' An Inferred Mineral Resource is that part of a Mineral Resource for which quantity and grade or quality are estimated on the basis of limited geological evidence and sampling. Geological evidence is sufficient to imply but not verify geological and grade or quality continuity. An Inferred Mineral Resource has a lower level of confidence than that applying to an Indicated Mineral Resource and must not be converted to a Mineral Reserve. It is reasonably expected that the majority of Inferred Mineral Resources could be upgraded to Indicated Mineral Resources with continued exploration. 'Measured Mineral Resource' A Measured Mineral Resource is that part of a Mineral Resource for which quantity, grade or quality, densities, shape, and physical characteristics are estimated with confidence sufficient to allow the application of Modifying Factors to support detailed mine planning and final evaluation of the economic viability of the deposit. Geological evidence is derived from detailed and reliable exploration, sampling and testing and is sufficient to confirm geological and grade or quality continuity between points of observation. A Measured Mineral Resource has a higher level of confidence than that applying to either an Indicated Mineral Resource or an Inferred Mineral Resource. It may be converted to a Proven Mineral Reserve or to a Probable Mineral Reserve. 'mineralisation' the concentration of metals and their chemical compounds within a body of rock. 'mineralised' refers to rock which contains minerals e.g. iron, copper, gold. 'Mineral Resource' A Mineral Resource is a concentration or occurrence of solid material of economic interest in or on the Earth's crust in such form, grade or quality and quantity that there are reasonable prospects for eventual economic extraction. The location, quantity, grade or quality, continuity and other geological characteristics of a Mineral Resource are known, estimated or interpreted from specific geological evidence and knowledge, including sampling. 'Mineral Reserve' A Mineral Reserve is the economically mineable part of a Measured and/or Indicated Mineral Resource. It includes diluting materials and allowances for losses, which may occur when the material is mined or extracted and is defined by studies at Pre-Feasibility or Feasibility level as appropriate that include application of Modifying Factors. Such studies demonstrate that, at the time of reporting, extraction could reasonably be justified. 'Mo-Bi-As-Te-W-Sn' Molybdenum-Bismuth-Arsenic-Tellurium-Tungsten-Tin 'monzogranite' a biotite rich granite, often part of the later-stage emplacement of a larger granite body. 'mt' means million tonnes. 'ore' means a metal or mineral or a combination of these of sufficient value as to quality and quantity to enable it to be mined at a profit. 'oxides' are near surface bed-rock which has been weathered and oxidised by long term exposure to the effects of water and air. 'ppm' means parts per million. 'Probable Mineral Reserve' is the economically mineable part of an Indicated and, in some circumstances, a Measured Mineral Resource demonstrated by at least a Preliminary Feasibility Study. This Study must include adequate information on mining, processing, metallurgical, economic, and other relevant factors that demonstrate, at the time of reporting, that economic extraction can be justified. 'Proven Mineral Reserve' is the economically mineable part of a Measured Mineral Resource. A Proven Mineral Reserve implies a high degree of confidence in the Modifying Factors. 'saprolite' is a weathered or decomposed clay-rich rock. 'sulphide' refers to minerals consisting of a chemical combination of sulphur with a metal. 'vein' is a generic term to describe an occurrence of mineralised rock within an area of non-mineralised rock. 'VTEM' refers to versa time domain electromagnetic, a particular variant of time-domain electromagnetic geophysical survey to prospect for conductive bodies below surface. 'XRF' X-ray Fluorescence (XRF) is a spectrometric technique used to perform elemental analysis non-destructively on samples Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
